Fig. 1.

SirT1 ASO is effective and decreases basal glucose levels in T2DM. (A) Body weight of pair-fed rats. (B) SirT1 ASO decreased liver mRNA and (C) SirT1 hepatic protein (normalized to total STAT3). SirT1 ASO decreased WAT SirT1 (D), but not muscle SirT1 mRNA (E), and slightly decreased BAT SirT1 mRNA (F). In WAT, PPARγ (E) and PPARγ2 (F), mRNA were decreased with SirT1 ASO. Fasting basal glucose values in the T2DM rat model were decreased (H), but not basal insulin (I) or glucagon. (n = 6–19 per group.) *, P < 0.05; **, P < 0.005.